Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2023 Annual Meeting | C111 - Multiple Sclerosis Disease-modifying Treatment

Monday 04/24/23
03:30 PM - 05:30 PM EST Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Jacqueline Bernard, MD, FAAN
Multiple Sclerosis
Participants will get a review of indications for using FDA-approved disease-modifying treatments (DMTs) for different phenotypes of multiple sclerosis. AAN guidelines for starting, switching and stopping DMTs will be incorporated into several clinical scenarios. Polling questions will be integrated into the lecture experience in order to engage the audience and encourage vigorous discussion. Treatment decisions related to pregnancy, breastfeeding, and COVID-19 management will be emphasized. Mechanism of action, adverse effects of major groups of DMTs will be discussed as well as recommended surveillance monitoring.

This program is supported in part by educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals.

The Academy was solely responsible, with no influence from the industry supporters, for selection of content, format, presenters, and moderators of this CME program, and the speakers have not been contacted or influenced in any way by the industry supporters with regard to this CME program.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice
Advanced Practice Provider
Fellow, Resident, General Neurologist, Advanced Practice Provider
Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
03:30 PM - 04:15 PM EST Speaker Overview of MS Phenotypes, McDonald Criteria, NEDA Concepts, Caveats in Diagnosis, Management, and Strategies
Jacqueline Bernard, MD, FAAN
04:15 PM - 05:15 PM EST Speaker Updates on Newer DMTs and Emerging Therapies, Special Considerations During COVID.
Chris Hollen, MD
05:15 PM - 05:30 PM EST Discussion Questions and Answers
Jacqueline Bernard, MD, FAAN, Chris Hollen, MD
Faculty Disclosures
Jacqueline Bernard, MD, FAAN Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bernard has received publishing royalties from a publication relating to health care.
Chris Hollen, MD Dr. Hollen has nothing to disclose.